Literature DB >> 24901565

Cardiomyopathy, mitochondria and Barth syndrome: iPSCs reveal a connection.

Kunil K Raval1, Timothy J Kamp1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24901565     DOI： 10.1038/nm.3592

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  8 in total

1.  Muscular thin films for building actuators and powering devices.

Authors:  Adam W Feinberg; Alex Feigel; Sergey S Shevkoplyas; Sean Sheehy; George M Whitesides; Kevin Kit Parker
Journal:  Science       Date:  2007-09-07       Impact factor: 47.728

Review 2.  The functions of cardiolipin in cellular metabolism-potential modifiers of the Barth syndrome phenotype.

Authors:  Vaishnavi Raja; Miriam L Greenberg
Journal:  Chem Phys Lipids       Date:  2014-01-17       Impact factor: 3.329

3.  The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation.

Authors:  Jennifer R Hom; Rodrigo A Quintanilla; David L Hoffman; Karen L de Mesy Bentley; Jeffery D Molkentin; Shey-Shing Sheu; George A Porter
Journal:  Dev Cell       Date:  2011-09-13       Impact factor: 12.270

4.  An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes.

Authors:  P G Barth; H R Scholte; J A Berden; J M Van der Klei-Van Moorsel; I E Luyt-Houwen; E T Van 't Veer-Korthof; J J Van der Harten; M A Sobotka-Plojhar
Journal:  J Neurol Sci       Date:  1983-12       Impact factor: 3.181

5.  Induced pluripotent stem cell lines derived from human somatic cells.

Authors:  Junying Yu; Maxim A Vodyanik; Kim Smuga-Otto; Jessica Antosiewicz-Bourget; Jennifer L Frane; Shulan Tian; Jeff Nie; Gudrun A Jonsdottir; Victor Ruotti; Ron Stewart; Igor I Slukvin; James A Thomson
Journal:  Science       Date:  2007-11-20       Impact factor: 47.728

6.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

7.  Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies.

Authors:  Gang Wang; Megan L McCain; Luhan Yang; Aibin He; Francesco Silvio Pasqualini; Ashutosh Agarwal; Hongyan Yuan; Dawei Jiang; Donghui Zhang; Lior Zangi; Judith Geva; Amy E Roberts; Qing Ma; Jian Ding; Jinghai Chen; Da-Zhi Wang; Kai Li; Jiwu Wang; Ronald J A Wanders; Wim Kulik; Frédéric M Vaz; Michael A Laflamme; Charles E Murry; Kenneth R Chien; Richard I Kelley; George M Church; Kevin Kit Parker; William T Pu
Journal:  Nat Med       Date:  2014-05-11       Impact factor: 53.440

8.  A novel X-linked gene, G4.5. is responsible for Barth syndrome.

Authors:  S Bione; P D'Adamo; E Maestrini; A K Gedeon; P A Bolhuis; D Toniolo
Journal:  Nat Genet       Date:  1996-04       Impact factor: 38.330
  8 in total
  4 in total

Review 1.  Barth Syndrome: From Mitochondrial Dysfunctions Associated with Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell Studies.

Authors:  Ana Saric; Karine Andreau; Anne-Sophie Armand; Ian M Møller; Patrice X Petit
Journal:  Front Genet       Date:  2016-01-20       Impact factor: 4.599

Review 2.  hiPSC-Derived Cardiac Tissue for Disease Modeling and Drug Discovery.

Authors:  Junjun Li; Ying Hua; Shigeru Miyagawa; Jingbo Zhang; Lingjun Li; Li Liu; Yoshiki Sawa
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

Review 3.  Successful management of Barth syndrome: a systematic review highlighting the importance of a flexible and multidisciplinary approach.

Authors:  Stacey Reynolds
Journal:  J Multidiscip Healthc       Date:  2015-07-29

Review 4.  Mitochondrial Protein Homeostasis and Cardiomyopathy.

Authors:  Emily Wachoski-Dark; Tian Zhao; Aneal Khan; Timothy E Shutt; Steven C Greenway
Journal:  Int J Mol Sci       Date:  2022-03-20       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.